TEA

(redirected from thromboendarterectomy)
Also found in: Medical.
AcronymDefinition
TEATexas Education Agency
TEATaxed Enough Already (tea party; political activism)
TEATransportation Equity Act for the 21st Century
TEATriethanolamine
TEATennessee Education Association (Nashville, TN)
TEAThemed Entertainment Association
TEATriethylamine
TEATetraethylammonium
TEATiny Encryption Algorithm (developed by David Wheeler and Roger Needham at the Computer Laboratory of Cambridge University)
TEATeachers Experiencing Antarctica and the Arctic
TEATwin Engine Aircraft
TEATransportation Enhancement Activities (Canada)
TEAThromboendarterectomy
TEAToronto Environmental Alliance
TEATargeted Employment Area
TEATransitional Employment Assistance (State of Arkansas)
TEATransportation Engineering Agency
TEATemperate East Asia
TEATrace Element Analysis
TEATactical Espionage Action (game)
TEATorque Equilibrium Attitude
TEATelevision Equipment Associates (Brewster, NY)
TEATriethyl Aluminum
TEATreasury Enforcement Agent
TEAThe Electronic Alveary (word search program)
TEATraining Effectiveness Analysis
TEATechnology for Enabling Awareness
TEAToronto Entomologists' Association
TEATransferred Episcopal Arrangements
TEATerminal Education Age
TEATraining Employment Advice Shop
TEATechnical Exchange Agreement
TEATransversely Excited Atmosphere
TEATiming Error Avoidance
TEATechnology Exchange Agreement
TEATransportability Engineering Analysis
TEATechnical Engineering Authority
TEATactical Engineering & Analysis, Inc.
TEATargeted Enforcement Area (police warning radar)
TEATirupur Exports Association (India)
TEATwinsburg Education Association (Twinsburg, Ohio)
TEATechnicien en Entretien d'Aéronefs
TEATen Eyck Associates
TEATransient Effect Area
TEATelephone Extension Alert
TEATicket Entry Automation
TEATransportation Engineering Agreement
TEATemporary Employment Agency (various locations)
TEATexas Electronics Association, LLC (Fort Worth, TX)
TEATerminal Electron Acceptor (cellular respiration)
TEATidy Enforcement Agency (gaming clan)
TEATechnical Excellence Award (various organizations)
TEATrade Expansion Act
TEATechno-Economic Analysis
References in periodicals archive ?
Emergent pulmonary thromboendarterectomy with percutaneous cardiopulmonary support system for chronic thromboembolic pulmonary hypertension.
Improvement of tricuspid regurgitation after pulmonary thromboendarterectomy.
75; thromboendarterectomy is performed to treat occlusion of the carotid artery, and the black:white ratio was 0.
Also, an embolus from the occluding thrombus into a more distal cerebral artery would not be removed by the thromboendarterectomy and would require thrombolytic therapy or a second, intracranial surgical embolectomy to remove.
The Company previously announced favorable results from a preliminary analysis of a Phase II clinical trial with Cylexin evaluating its ability to reduce reperfusion injury following the surgical removal of chronic blood clots from the lungs in an orphan drug indication, pulmonary thromboendarterectomy (PDE).
PAS was confirmed in five patients, and chronic thromboembolic pulmonary hypertension (CTEPH) was considered the correct diagnosis with the histological findings from CGFB and confirmed after pulmonary thromboendarterectomy later [Figure 3].
Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
Survival was 81% at 3 years in a group of 88 patients who underwent thromboendarterectomy.
More concretely, procedures are divided into six categories: cardiovascular catheterization, coronary artery bypass graft (CABG), abdominal aortic aneurysm repair (AAA), carotid thromboendarterectomy, percutaneous transluminal coronary angioplasty (PTCA), and pacemaker insertion.
The nine categories were colectomy (-9 percent), cholecystectomy (-7 percent), other major procedures (-2 percent), thromboendarterectomy (-10 percent), pacemaker insertion (-8 percent), hip fracture repair (-7 percent), inguinal hernia repair (-6 percent), upper gastrointestinal endoscopy (-5 percent), and sigmoidoscopy (-6 percent).
SAN DIEGO--(BUSINESS WIRE)--April 30, 1996--Cytel Corporation (NASDAQ:CYTL) announced today that results of a Phase II clinical trial with its selectin blocker, Cylexin(TM), demonstrated evidence of a clinical benefit suggesting reduction of reperfusion injury following pulmonary thromboendarterectomy (PTE), the surgical removal of chronic blood clots from the lungs.